MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561560 | Name: VE-465

Description:

WARNING: This product is for research use only, not for human or veterinary use.

VE-465 is a novel Aurora kinase inhibitor. The Aurora kinase family of kinases (Aurora A, B, and C) are involved in multiple mitotic events, and aberrant expression of these kinases is associated with tumorigenesis.

Chemical Structure

VE-465
VE-465
CAS#639089-73-9

Theoretical Analysis

MedKoo Cat#: 561560

Name: VE-465

CAS#: 639089-73-9

Chemical Formula: C22H28N8OS

Exact Mass: 452.2107

Molecular Weight: 452.58

Elemental Analysis: C, 58.39; H, 6.24; N, 24.76; O, 3.54; S, 7.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
VE-465; VE 465; VE465;
IUPAC/Chemical Name
N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-propanamide
InChi Key
LCQYMDMUCJFFKN-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H28N8OS/c1-4-21(31)23-16-5-7-17(8-6-16)32-22-25-18(24-19-13-15(2)27-28-19)14-20(26-22)30-11-9-29(3)10-12-30/h5-8,13-14H,4,9-12H2,1-3H3,(H,23,31)(H2,24,25,26,27,28)
SMILES Code
CCC(NC1=CC=C(SC2=NC(NC3=NNC(C)=C3)=CC(N4CCN(C)CC4)=N2)C=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 452.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Falchook GS, Bastida CC, Kurzrock R. Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Semin Oncol. 2015 Dec;42(6):832-48. doi: 10.1053/j.seminoncol.2015.09.022. Epub 2015 Sep 24. Review. PubMed PMID: 26615129. 2: Cooper S, Giles FJ, Savona MR. Overcoming resistance in chronic myelogenous leukemia. Leuk Lymphoma. 2009 Nov;50(11):1785-93. doi: 10.3109/10428190903267559. Review. PubMed PMID: 19883308. 3: Liang YQ, Chen BA, Chen YL. [Research progress on aurora kinase inhibitor MK-0457 in therapy for some hematological malignancies -- review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):810-5. Review. Chinese. PubMed PMID: 19549414. 4: Chen XG, Zhang Y. [Recent advance in the study of novel anti-tumor targets and drugs--aurora kinase and Pin1]. Yao Xue Xue Bao. 2009 Mar;44(3):264-9. Review. Chinese. PubMed PMID: 19449522. 5: Hasselbalch HC, Birgens H, Dufva IH, Dalseg AM, Brown Pde N, Jensen MK, Vangsted A. [Novel medical treatment modalities in hematology]. Ugeskr Laeger. 2008 Jun 9;170(24):2115-9. Review. Danish. PubMed PMID: 18565291. 6: Li SA, Lam LK, Ahmed N, Hontz AE, Li JJ. Estrogen-induced breast oncogenesis: modulation by an Aurora kinase inhibitor. Adv Exp Med Biol. 2008;617:213-20. doi: 10.1007/978-0-387-69080-3_20. Review. PubMed PMID: 18497045. 7: Thomas X. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. Bull Cancer. 2007 Oct;94(10):871-80. Review. French. PubMed PMID: 17964981. 8: Kimura S. [Novel anti-CML agents beyond imatinib]. Rinsho Ketsueki. 2007 Jun;48(6):475-84. Review. Japanese. PubMed PMID: 17633095. 9: Doggrell SA. Dawn of Aurora kinase inhibitors as anticancer drugs. Expert Opin Investig Drugs. 2004 Sep;13(9):1199-201. Review. PubMed PMID: 15330750.